Copyright Reports & Markets. All rights reserved.

Global Gastric Motility Disorder Drug Market Insights, Forecast to 2025

Request for Sample of this report
Buy now

Table of Contents

    1 Study Coverage

    • 1.1 Gastric Motility Disorder Drug Product
    • 1.2 Market Segments
    • 1.3 Key Manufacturers Covered
    • 1.4 Market by Type
      • 1.4.1 Global Gastric Motility Disorder Drug Market Size Growth Rate by Product
      • 1.4.2 Velusetrag
      • 1.4.3 Ipamorelin
      • 1.4.4 TD-8954
      • 1.4.5 Others
    • 1.5 Market by End User
      • 1.5.1 Global Gastric Motility Disorder Drug Market Size Growth Rate by End User
      • 1.5.2 Hospital
      • 1.5.3 Clinic
      • 1.5.4 Home Use
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Executive Summary

    • 2.1 Global Gastric Motility Disorder Drug Market Size
      • 2.1.1 Global Gastric Motility Disorder Drug Revenue 2014-2025
      • 2.1.2 Global Gastric Motility Disorder Drug Sales 2014-2025
    • 2.2 Gastric Motility Disorder Drug Growth Rate by Regions
      • 2.2.1 Global Gastric Motility Disorder Drug Sales by Regions
      • 2.2.2 Global Gastric Motility Disorder Drug Revenue by Regions

    3 Breakdown Data by Manufacturers

    • 3.1 Gastric Motility Disorder Drug Sales by Manufacturers
      • 3.1.1 Gastric Motility Disorder Drug Sales by Manufacturers
      • 3.1.2 Gastric Motility Disorder Drug Sales Market Share by Manufacturers
      • 3.1.3 Global Gastric Motility Disorder Drug Market Concentration Ratio (CR5 and HHI)
    • 3.2 Gastric Motility Disorder Drug Revenue by Manufacturers
      • 3.2.1 Gastric Motility Disorder Drug Revenue by Manufacturers (2014-2019)
      • 3.2.2 Gastric Motility Disorder Drug Revenue Share by Manufacturers (2014-2019)
    • 3.3 Gastric Motility Disorder Drug Price by Manufacturers
    • 3.4 Gastric Motility Disorder Drug Manufacturing Base Distribution, Product Types
      • 3.4.1 Gastric Motility Disorder Drug Manufacturers Manufacturing Base Distribution, Headquarters
      • 3.4.2 Manufacturers Gastric Motility Disorder Drug Product Type
      • 3.4.3 Date of International Manufacturers Enter into Gastric Motility Disorder Drug Market
    • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Product

    • 4.1 Global Gastric Motility Disorder Drug Sales by Product
    • 4.2 Global Gastric Motility Disorder Drug Revenue by Product
    • 4.3 Gastric Motility Disorder Drug Price by Product

    5 Breakdown Data by End User

    • 5.1 Overview
    • 5.2 Global Gastric Motility Disorder Drug Breakdown Data by End User

    6 North America

    • 6.1 North America Gastric Motility Disorder Drug by Countries
      • 6.1.1 North America Gastric Motility Disorder Drug Sales by Countries
      • 6.1.2 North America Gastric Motility Disorder Drug Revenue by Countries
      • 6.1.3 United States
      • 6.1.4 Canada
      • 6.1.5 Mexico
    • 6.2 North America Gastric Motility Disorder Drug by Product
    • 6.3 North America Gastric Motility Disorder Drug by End User

    7 Europe

    • 7.1 Europe Gastric Motility Disorder Drug by Countries
      • 7.1.1 Europe Gastric Motility Disorder Drug Sales by Countries
      • 7.1.2 Europe Gastric Motility Disorder Drug Revenue by Countries
      • 7.1.3 Germany
      • 7.1.4 France
      • 7.1.5 UK
      • 7.1.6 Italy
      • 7.1.7 Russia
    • 7.2 Europe Gastric Motility Disorder Drug by Product
    • 7.3 Europe Gastric Motility Disorder Drug by End User

    8 Asia Pacific

    • 8.1 Asia Pacific Gastric Motility Disorder Drug by Countries
      • 8.1.1 Asia Pacific Gastric Motility Disorder Drug Sales by Countries
      • 8.1.2 Asia Pacific Gastric Motility Disorder Drug Revenue by Countries
      • 8.1.3 China
      • 8.1.4 Japan
      • 8.1.5 Korea
      • 8.1.6 India
      • 8.1.7 Australia
      • 8.1.8 Indonesia
      • 8.1.9 Malaysia
      • 8.1.10 Philippines
      • 8.1.11 Thailand
      • 8.1.12 Vietnam
      • 8.1.13 Singapore
    • 8.2 Asia Pacific Gastric Motility Disorder Drug by Product
    • 8.3 Asia Pacific Gastric Motility Disorder Drug by End User

    9 Central & South America

    • 9.1 Central & South America Gastric Motility Disorder Drug by Countries
      • 9.1.1 Central & South America Gastric Motility Disorder Drug Sales by Countries
      • 9.1.2 Central & South America Gastric Motility Disorder Drug Revenue by Countries
      • 9.1.3 Brazil
    • 9.2 Central & South America Gastric Motility Disorder Drug by Product
    • 9.3 Central & South America Gastric Motility Disorder Drug by End User

    10 Middle East and Africa

    • 10.1 Middle East and Africa Gastric Motility Disorder Drug by Countries
      • 10.1.1 Middle East and Africa Gastric Motility Disorder Drug Sales by Countries
      • 10.1.2 Middle East and Africa Gastric Motility Disorder Drug Revenue by Countries
      • 10.1.3 GCC Countries
      • 10.1.4 Turkey
      • 10.1.5 Egypt
      • 10.1.6 South Africa
    • 10.2 Middle East and Africa Gastric Motility Disorder Drug by Product
    • 10.3 Middle East and Africa Gastric Motility Disorder Drug by End User

    11 Company Profiles

    • 11.1 Theravance, Inc.
      • 11.1.1 Theravance, Inc. Company Details
      • 11.1.2 Company Business Overview
      • 11.1.3 Theravance, Inc. Gastric Motility Disorder Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.1.4 Theravance, Inc. Gastric Motility Disorder Drug Products Offered
      • 11.1.5 Theravance, Inc. Recent Development
    • 11.2 Helsinn Healthcare S.A.
      • 11.2.1 Helsinn Healthcare S.A. Company Details
      • 11.2.2 Company Business Overview
      • 11.2.3 Helsinn Healthcare S.A. Gastric Motility Disorder Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.2.4 Helsinn Healthcare S.A. Gastric Motility Disorder Drug Products Offered
      • 11.2.5 Helsinn Healthcare S.A. Recent Development
    • 11.3 Concert Pharmaceuticals, Inc.
      • 11.3.1 Concert Pharmaceuticals, Inc. Company Details
      • 11.3.2 Company Business Overview
      • 11.3.3 Concert Pharmaceuticals, Inc. Gastric Motility Disorder Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.3.4 Concert Pharmaceuticals, Inc. Gastric Motility Disorder Drug Products Offered
      • 11.3.5 Concert Pharmaceuticals, Inc. Recent Development
    • 11.4 Targacept, Inc.
      • 11.4.1 Targacept, Inc. Company Details
      • 11.4.2 Company Business Overview
      • 11.4.3 Targacept, Inc. Gastric Motility Disorder Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.4.4 Targacept, Inc. Gastric Motility Disorder Drug Products Offered
      • 11.4.5 Targacept, Inc. Recent Development
    • 11.5 ChironWells GmbH
      • 11.5.1 ChironWells GmbH Company Details
      • 11.5.2 Company Business Overview
      • 11.5.3 ChironWells GmbH Gastric Motility Disorder Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.5.4 ChironWells GmbH Gastric Motility Disorder Drug Products Offered
      • 11.5.5 ChironWells GmbH Recent Development

    12 Future Forecast

    • 12.1 Gastric Motility Disorder Drug Market Forecast by Regions
      • 12.1.1 Global Gastric Motility Disorder Drug Sales Forecast by Regions 2019-2025
      • 12.1.2 Global Gastric Motility Disorder Drug Revenue Forecast by Regions 2019-2025
    • 12.2 Gastric Motility Disorder Drug Market Forecast by Product
      • 12.2.1 Global Gastric Motility Disorder Drug Sales Forecast by Product 2019-2025
      • 12.2.2 Global Gastric Motility Disorder Drug Revenue Forecast by Product 2019-2025
    • 12.3 Gastric Motility Disorder Drug Market Forecast by End User
    • 12.4 North America Gastric Motility Disorder Drug Forecast
    • 12.5 Europe Gastric Motility Disorder Drug Forecast
    • 12.6 Asia Pacific Gastric Motility Disorder Drug Forecast
    • 12.7 Central & South America Gastric Motility Disorder Drug Forecast
    • 12.8 Middle East and Africa Gastric Motility Disorder Drug Forecast

    13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

    • 13.1 Market Opportunities and Drivers
    • 13.2 Market Challenges
    • 13.3 Market Risks/Restraints
    • 13.4 Macroscopic Indicators

    14 Value Chain and Sales Channels Analysis

    • 14.1 Value Chain Analysis
    • 14.2 Gastric Motility Disorder Drug Customers
    • 14.3 Sales Channels Analysis
      • 14.3.1 Sales Channels
      • 14.3.2 Distributors

    15 Research Findings and Conclusion

      16 Appendix

      • 16.1 Research Methodology
        • 16.1.1 Methodology/Research Approach
        • 16.1.2 Data Source
      • 16.2 Author Details

      The global Gastric Motility Disorder Drug market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to define, segment, and project the size of the Gastric Motility Disorder Drug market based on company, product type, end user and key regions.

      This report studies the global market size of Gastric Motility Disorder Drug in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Gastric Motility Disorder Drug in these regions.
      This research report categorizes the global Gastric Motility Disorder Drug market by top players/brands, region, type and end user. This report also studies the global Gastric Motility Disorder Drug market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

      The following manufacturers are covered in this report, with sales, revenue, market share for each company:
      Theravance, Inc.
      Helsinn Healthcare S.A.
      Concert Pharmaceuticals, Inc.
      Targacept, Inc.
      ChironWells GmbH

      Market size by Product
      Velusetrag
      Ipamorelin
      TD-8954
      Others
      Market size by End User
      Hospital
      Clinic
      Home Use

      Market size by Region
      North America
      United States
      Canada
      Mexico
      Asia-Pacific
      China
      India
      Japan
      South Korea
      Australia
      Indonesia
      Singapore
      Malaysia
      Philippines
      Thailand
      Vietnam
      Europe
      Germany
      France
      UK
      Italy
      Spain
      Russia
      Central & South America
      Brazil
      Rest of Central & South America
      Middle East & Africa
      GCC Countries
      Turkey
      Egypt
      South Africa

      The study objectives of this report are:
      To study and analyze the global Gastric Motility Disorder Drug market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
      To understand the structure of Gastric Motility Disorder Drug market by identifying its various subsegments.
      To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
      Focuses on the key global Gastric Motility Disorder Drug companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
      To project the value and sales volume of Gastric Motility Disorder Drug submarkets, with respect to key regions.
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

      In this study, the years considered to estimate the market size of Gastric Motility Disorder Drug are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      This report includes the estimation of market size for value (million US$) and volume (K Pcs). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Gastric Motility Disorder Drug market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now